Oct 21, 2021

Mawazo Writing Africa

Writing about the main

After 30 years’ search, world gets first ever malaria vaccine

The World Health Organization (WHO) officially recommended the widespread use of the shock known as RTS, S on Wednesday after trials in Kenya, Ghana and Malawi.

Kenya became the third country to conduct clinical trials for accept the vaccine.

The trade name is Mosquirix and was jointly developed by British pharmaceutical giant GlaxoSmithKline, PATH and African research institutes.

This is a “historic day”. “Since the vaccine took 30 years to develop, said WHO Director-General Dr. Tedros Adhanom Ghebreyesus.

“We still have a long way to go. But that’s a long way to go. Malaria The vaccine is a gift to the world, but its value will be felt most in Africa, where the malaria burden is greatest, “he said.

” I thank the researchers in Africa who the data and intelligence that influenced that decision – this is a vaccine that was developed in Africa by African scientists. “

The dream of a malaria vaccine, he said, is” a long one cherished but unattainable dream “and the vaccine, which took more than 30 years to develop, will change the course of public health.

The use of the new vaccine alongside existing tools to prevent malaria, he said, could save tens of thousands of young lives each year.

“This long-awaited malaria vaccine is a breakthrough in science, child health and malaria control,” he said.

More than 800,000 children in the three African pil According to the WHO, otländer has been given at least one dose of the vaccine as part of the normal vaccination programs for children since 2019. Experts say the vaccine was shown to be safe and prevented malaria 30 percent of the severe cases.

Kemri’s joy knows no bounds.

“Having more than 2 million doses of the vaccine through routine vaccination systems In the 3 pilot countries, and hundreds of thousands of children have been vaccinated, there is no evidence that the safety signals seen in the previous Phase 3 study are caused by the vaccine, ”Kemri said in an official statement.

“The vaccine has been shown to be safe and effective in the pilots and a number of other recent RTS, S clinical trials. Assessment at the time of regulatory review and by the Clinical Trials Data Safety Monitoring Board was that it was The observations were incidental and this pilot program has now resolved. “

The effects of this vaccine on, in addition to current malaria control measures, says Kemri, is significant and can lead to great and significant reductions in diseases and deaths and the burden on health systems.

“At least 3,000 children die from malaria every day in Africa. RTS, S malaria vaccine is a welcome addition to the existing anti-malarial arsenal. We applaud the galaxy of researchers and funders involved in the breakthrough of the RTS, S vaccine in malaria control. Good day for science! ”Kemri tweeted.

On a phone call with the nation, Aaron Samuels, the director of the Kenyan Malaria Program at the US Centers for the Control and Prevention of Diseases (CDC), this success as historic.

“I think this is a historic event for the world, and especially for Kenya, where there is systemic malaria. This vaccine is being used for children across Africa south of the Said Samuels, who is also the lead researcher for the malaria vaccine.

< p> “I’m just proud to be still alive, but now we still have to work a lot on the implementation, how it is financed, who finances it and what role the African heads of state and government have to play because we have to come together, around make those decisions. ”

In an official statement, PATH, a nonprofit global health organization based in Seattle, USA, said it was gratifying to know that a malaria vaccine specially developed for African children was about to be launched could be more widely available.

“This is especially true now as progress in the fight against malaria has stalled in parts of Africa and children remain at increased risk of dying from the disease” said Dr. Nathalie Mugala, Head of Africa Region at PATH.

Last year, President Uhuru Kenyatta launched the “Zero Malaria Starts With Me” campaign as the person at the head of the Africa Leaders Malaria Alliance. This vaccine could be a solution to this goal.

In February the government launched the Council to Fight Malaria (EMC), which consists of 12 members. One of his strategies is malaria prevention.

Kenya is the fifth country to join the EMC initiative.

The hard work of the Kenya Medical Research Institute (Kemri) and the contribution of children in Kericho, Kisumu and Kilifi have finally paid off by giving the world their first malaria vaccine.

The World Health Organization (WHO) on Wednesday officially recommended the widespread use of the jab known as RTS, S, after Studies in Kenya, Ghana and Malawi.

Kenya became the third country to introduce clinical trials for the vaccine in 2019.

The trade name is Mosquirix and was jointly developed by the British pharmaceutical giant GlaxoSmithKline , PATH and African research institutes.

This is “a historic day” as it took 30 years to develop the vaccine, said WHO Director General Dr. Tedros Adhanom Ghebreyesus.

“We still have a long way to go. But this is a long way to go. The malaria vaccine is a gift to the world, but it’s worth getting in Africa on be most noticeable where the malaria burden is greatest, “he said.

” I thank the researchers in Africa for providing the data and insight that led to this decision – this is a vaccine in Africa developed by African scientists. “

The dream of a malaria vaccine was” a long-cherished but unattainable dream “and the development of the vaccine took more than 30 years, is the course of the public Changing health.

Using the new vaccine along with existing tools to prevent malaria, he said, could save tens of thousands of young lives each year.

“This is the long-awaited malaria vaccine is a breakthrough in the science of child health e time and malaria control, ”he said.

According to the WHO, more than 800,000 children in the three African pilot countries have been given at least one dose of the vaccine since 2019 as part of normal children’s vaccination programs, with experts saying that the vaccine has been shown to be safe and 30 percent of severe malaria cases.

Kemri’s joy knows no bounds.

“Having passed more than 2 million doses of the vaccine through routine vaccination systems in the 3 pilot countries have been administered and hundreds of thousands of children have been vaccinated, there is no evidence that the safety signals seen in the previous Phase 3 study were caused by the vaccine, ”Kemri said in an official statement.

“The vaccine has been shown to be safe and effective in the pilot projects and in a number of other recent RTS, S clinical studies. The assessment at the time of regulatory review and by the Clinical Trials Data Safety Monitoring Board was that the observations were incidental and this pilot program has now resolved. “

The effects of this vaccine on additional Current malaria control measures, says Kemri, are significant and can lead to significant and significant reductions in disease and deaths and the burden on health systems.

“At least 3,000 children die from malaria every day in Africa. RTS, S malaria vaccine is a welcome addition to the existing arsenal against malaria. We salute the galaxy of researchers and funders involved in the RTS, S vaccine’s breakthrough in malaria control. A good day for science! “Kemri followed with one Tweet.

In a phone conversation with the nation, Aaron Samuels, the director of the Kenya Malaria Program, described ms the US Centers for Disease Control and Prevention (CDC) considered this success historic.

“I think this is a historic event for the world and especially for Kenya, where there is systemic malaria gives. This vaccine will save lives for children across sub-Saharan Africa. I want Kemri. thank you and celebrate him, who were instrumental in making this recommendation and this vaccine a success, “said Samuels, who is also the lead researcher for the malaria vaccine.

” I’m just proud to be still alive, but now we still have to work a lot on how it is financed, who finances it and what role the African heads of state and government have to play because we have to come together to make these decisions. ”< / p>

In an official statement, PATH, a not-for-profit global health organization based in Seattle, USA, said it was gratifying to know that a malaria vaccine specially developed for African children could soon become more widely available. < / p>

“This is especially true now as progress in the fight against malaria has stalled in parts of the Africa region and children remain at increased risk of developing the disease ready to die, ”said Dr. Nathalie Mugala, Head of Africa Region at PATH.

Last year, President Uhuru Kenyatta launched the “Zero Malaria Starts With Me” campaign as the person at the head of the Africa Leaders Malaria Alliance. This vaccine could be a solution to this goal.

In February the government set up the Council to Fight Malaria (EMC), which consists of 12 members. One of his strategies is malaria prevention.

Kenya is the fifth country to join the EMC initiative.

[emailprotected]; [emailprotected]